Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

Elevated plasma levels and platelet-associated expression of the pro-thrombotic and pro-inflammatory protein, TNFSF14 (LIGHT), in sickle cell disease.

Garrido VT, Proença-Ferreira R, Dominical VM, Traina F, Bezerra MA, de Mello MR, Colella MP, Araújo AS, Saad ST, Costa FF, Conran N.

Br J Haematol. 2012 Sep;158(6):788-97. doi: 10.1111/j.1365-2141.2012.09218.x. Epub 2012 Jul 6.

PMID:
22775554
2.

Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy.

Lanaro C, Franco-Penteado CF, Albuqueque DM, Saad ST, Conran N, Costa FF.

J Leukoc Biol. 2009 Feb;85(2):235-42. doi: 10.1189/jlb.0708445. Epub 2008 Nov 12.

3.

Platelet-associated LIGHT (TNFSF14) mediates adhesion of platelets to human vascular endothelium.

Celik S, Langer H, Stellos K, May AE, Shankar V, Kurz K, Katus HA, Gawaz MP, Dengler TJ.

Thromb Haemost. 2007 Oct;98(4):798-805.

PMID:
17938804
4.

Endothelial activation by platelets from sickle cell anemia patients.

Proença-Ferreira R, Brugnerotto AF, Garrido VT, Dominical VM, Vital DM, Ribeiro Mde F, dos Santos ME, Traina F, Olalla-Saad ST, Costa FF, Conran N.

PLoS One. 2014 Feb 13;9(2):e89012. doi: 10.1371/journal.pone.0089012. eCollection 2014.

5.

Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammation.

Lee SP, Ataga KI, Orringer EP, Phillips DR, Parise LV.

Arterioscler Thromb Vasc Biol. 2006 Jul;26(7):1626-31. Epub 2006 Apr 6.

6.

Hydroxycarbamide reduces eosinophil adhesion and degranulation in sickle cell anaemia patients.

Pallis FR, Conran N, Fertrin KY, Olalla Saad ST, Costa FF, Franco-Penteado CF.

Br J Haematol. 2014 Jan;164(2):286-95. doi: 10.1111/bjh.12628. Epub 2013 Oct 28.

PMID:
24383847
7.

Circulating platelet and erythrocyte microparticles in young children and adolescents with sickle cell disease: Relation to cardiovascular complications.

Tantawy AA, Adly AA, Ismail EA, Habeeb NM, Farouk A.

Platelets. 2013;24(8):605-14. doi: 10.3109/09537104.2012.749397. Epub 2012 Dec 18.

PMID:
23249216
8.

Chronic inflammatory state in sickle cell anemia patients is associated with HBB(*)S haplotype.

Bandeira IC, Rocha LB, Barbosa MC, Elias DB, Querioz JA, Freitas MV, Gonçalves RP.

Cytokine. 2014 Feb;65(2):217-21. doi: 10.1016/j.cyto.2013.10.009. Epub 2013 Nov 27.

9.

Increased adhesive and inflammatory properties in blood outgrowth endothelial cells from sickle cell anemia patients.

Sakamoto TM, Lanaro C, Ozelo MC, Garrido VT, Olalla-Saad ST, Conran N, Costa FF.

Microvasc Res. 2013 Nov;90:173-9. doi: 10.1016/j.mvr.2013.10.002. Epub 2013 Oct 18.

PMID:
24144783
10.

Hydroxyurea corrects the dysregulated L-selectin expression and increased H(2)O(2) production of polymorphonuclear neutrophils from patients with sickle cell anemia.

Benkerrou M, Delarche C, Brahimi L, Fay M, Vilmer E, Elion J, Gougerot-Pocidalo MA, Elbim C.

Blood. 2002 Apr 1;99(7):2297-303.

12.
13.
14.

Platelet-activating factor in plasma of patients with sickle cell disease in steady state.

Oh SO, Ibe BO, Johnson C, Kurantsin-Mills J, Raj JU.

J Lab Clin Med. 1997 Aug;130(2):191-6.

PMID:
9280146
15.

Increased adhesive properties of platelets in sickle cell disease: roles for alphaIIb beta3-mediated ligand binding, diminished cAMP signalling and increased phosphodiesterase 3A activity.

Proença-Ferreira R, Franco-Penteado CF, Traina F, Saad ST, Costa FF, Conran N.

Br J Haematol. 2010 Apr;149(2):280-8. doi: 10.1111/j.1365-2141.2010.08087.x. Epub 2010 Feb 5.

PMID:
20136824
16.

The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles.

Gerotziafas GT, Van Dreden P, Chaari M, Galea V, Khaterchi A, Lionnet F, Stankovic-Stojanovic K, Blanc-Brude O, Woodhams B, Maier-Redelsperger M, Girot R, Hatmi M, Elalamy I.

Thromb Haemost. 2012 Jun;107(6):1044-52. doi: 10.1160/TH11-10-0689. Epub 2012 Apr 26.

PMID:
22535498
17.

A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation.

Jakubowski JA, Zhou C, Jurcevic S, Winters KJ, Lachno DR, Frelinger AL 3rd, Gupta N, Howard J, Payne CD, Mant TG.

Thromb Res. 2014 Feb;133(2):190-5. doi: 10.1016/j.thromres.2013.12.008. Epub 2013 Dec 7.

PMID:
24368019
18.

Activated monocytes and platelet-monocyte aggregates in patients with sickle cell disease.

Wun T, Cordoba M, Rangaswami A, Cheung AW, Paglieroni T.

Clin Lab Haematol. 2002 Apr;24(2):81-8.

PMID:
11985552
19.

Biomarkers of inflammation, growth factor, and coagulation activation in patients with sickle cell disease.

Qari MH, Dier U, Mousa SA.

Clin Appl Thromb Hemost. 2012 Mar-Apr;18(2):195-200. doi: 10.1177/1076029611420992. Epub 2011 Sep 23.

PMID:
21949038
20.

Altered levels of pro-inflammatory cytokines in sickle cell disease patients during vaso-occlusive crises and the steady state condition.

Keikhaei B, Mohseni AR, Norouzirad R, Alinejadi M, Ghanbari S, Shiravi F, Solgi G.

Eur Cytokine Netw. 2013 Mar;24(1):45-52. doi: 10.1684/ecn.2013.0328.

PMID:
23608554
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk